Hannah Ewald1, Matthias Briel, Danielle Vuichard, Veronika Kreutle, Andriy Zhydkov, Viktoria Gloy. 1. Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, Switzerland, Department of Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, Department of Endocrinology, Diabetology & Metabolism, University and Cantonal Hospital Aarau, Switzerland, Cantonal Hospital Aarau, Switzerland, Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland.
Abstract
BACKGROUND: Streptococcus pneumoniae is responsible for approximately 1.6 million yearly deaths worldwide. An up-to-date evidence base on the effects of pneumococcal conjugate vaccines (PCVs) on infectious diseases and mortality in any population or setting regardless of age or health status is currently lacking. METHODS: We systematically searched MEDLINE and EMBASE for pertinent randomized controlled trials (RCTs). Two reviewers independently screened 9498 titles/abstracts and 430 full-text papers for eligible trials. The outcomes of our meta-analysis were pooled using relative risks (RRs) with a random effects model or Peto's odds ratios (ORs) if event rates were :lt;1%. RESULTS: 21 RCTs comprising 361 612 individuals were included. PCVs reduced the risk for invasive pneumococcal disease (odds ratio [OR]: 0.43, 95% confidence interval [CI]: [0.36; 0.51]), all-cause acute otitis media (AOM) (RR: 0.93, 95% CI: [0.86; 1.00]), pneumococcal AOM (RR: 0.57, 95% CI: [0.39; 0.83]), allcause pneumonia (RR: 0.93, 95% CI: [0.89; 0.97]), and pneumococcal pneumonia (RR: 0.78, 95% CI: [0.62; 0.97]). We found no significant effect of PCVs on all-cause mortality (RR: 0.95, 95% CI: [0.88; 1.03]) or recurrent AOM (RR: 0.87, 95% CI: [0.72; 1.05]). CONCLUSION: PCVs are associated with large risk reductions for pneumococcal infectious diseases, smaller risk reductions for infectious diseases from any cause, and no significant effect on all-cause mortality.
BACKGROUND:Streptococcus pneumoniae is responsible for approximately 1.6 million yearly deaths worldwide. An up-to-date evidence base on the effects of pneumococcal conjugate vaccines (PCVs) on infectious diseases and mortality in any population or setting regardless of age or health status is currently lacking. METHODS: We systematically searched MEDLINE and EMBASE for pertinent randomized controlled trials (RCTs). Two reviewers independently screened 9498 titles/abstracts and 430 full-text papers for eligible trials. The outcomes of our meta-analysis were pooled using relative risks (RRs) with a random effects model or Peto's odds ratios (ORs) if event rates were :lt;1%. RESULTS: 21 RCTs comprising 361 612 individuals were included. PCVs reduced the risk for invasive pneumococcal disease (odds ratio [OR]: 0.43, 95% confidence interval [CI]: [0.36; 0.51]), all-cause acute otitis media (AOM) (RR: 0.93, 95% CI: [0.86; 1.00]), pneumococcal AOM (RR: 0.57, 95% CI: [0.39; 0.83]), allcause pneumonia (RR: 0.93, 95% CI: [0.89; 0.97]), and pneumococcal pneumonia (RR: 0.78, 95% CI: [0.62; 0.97]). We found no significant effect of PCVs on all-cause mortality (RR: 0.95, 95% CI: [0.88; 1.03]) or recurrent AOM (RR: 0.87, 95% CI: [0.72; 1.05]). CONCLUSION: PCVs are associated with large risk reductions for pneumococcal infectious diseases, smaller risk reductions for infectious diseases from any cause, and no significant effect on all-cause mortality.
Authors: Dirk Bassler; Matthias Briel; Victor M Montori; Melanie Lane; Paul Glasziou; Qi Zhou; Diane Heels-Ansdell; Stephen D Walter; Gordon H Guyatt; David N Flynn; Mohamed B Elamin; Mohammad Hassan Murad; Nisrin O Abu Elnour; Julianna F Lampropulos; Amit Sood; Rebecca J Mullan; Patricia J Erwin; Clare R Bankhead; Rafael Perera; Carolina Ruiz Culebro; John J You; Sohail M Mulla; Jagdeep Kaur; Kara A Nerenberg; Holger Schünemann; Deborah J Cook; Kristina Lutz; Christine M Ribic; Noah Vale; German Malaga; Elie A Akl; Ignacio Ferreira-Gonzalez; Pablo Alonso-Coello; Gerard Urrutia; Regina Kunz; Heiner C Bucher; Alain J Nordmann; Heike Raatz; Suzana Alves da Silva; Fabio Tuche; Brigitte Strahm; Benjamin Djulbegovic; Neill K J Adhikari; Edward J Mills; Femida Gwadry-Sridhar; Haresh Kirpalani; Heloisa P Soares; Paul J Karanicolas; Karen E A Burns; Per Olav Vandvik; Fernando Coto-Yglesias; Pedro Paulo M Chrispim; Tim Ramsay Journal: JAMA Date: 2010-03-24 Impact factor: 56.272
Authors: Tamara Pilishvili; Catherine Lexau; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Arthur Reingold; Ann Thomas; William Schaffner; Allen S Craig; Philip J Smith; Bernard W Beall; Cynthia G Whitney; Matthew R Moore Journal: J Infect Dis Date: 2010-01-01 Impact factor: 5.226
Authors: Katherine L O'Brien; Lara J Wolfson; James P Watt; Emily Henkle; Maria Deloria-Knoll; Natalie McCall; Ellen Lee; Kim Mulholland; Orin S Levine; Thomas Cherian Journal: Lancet Date: 2009-09-12 Impact factor: 79.321
Authors: Mark T Dransfield; Moon H Nahm; Meilan K Han; Sarah Harnden; Gerard J Criner; Fernando J Martinez; Paul D Scanlon; Prescott G Woodruff; George R Washko; John E Connett; Nicholas R Anthonisen; William C Bailey Journal: Am J Respir Crit Care Med Date: 2009-06-25 Impact factor: 21.405
Authors: Alexandre C Fortanier; Roderick P Venekamp; Chantal Wb Boonacker; Eelko Hak; Anne Gm Schilder; Elisabeth Am Sanders; Roger Amj Damoiseaux Journal: Cochrane Database Syst Rev Date: 2019-05-28
Authors: Joline Lh de Sévaux; Roderick P Venekamp; Vittoria Lutje; Eelko Hak; Anne Gm Schilder; Elisabeth Am Sanders; Roger Amj Damoiseaux Journal: Cochrane Database Syst Rev Date: 2020-11-24